Drug intelligence / Profile preview

ASP6282 + itraconazole

Development stage: Unknown
Lead developer: Astellas Pharma
Modality: Small Molecules
Administration: Oral

Overview

ASP6282 + itraconazole is an investigational combination used in clinical pharmacology studies to assess the drug-drug interaction between ASP6282, a small molecule under development by Astellas Pharma, and itraconazole, a strong CYP3A4 inhibitor and approved antifungal. ASP6282’s mechanism is not disclosed in available public information. The combination is not intended as a therapeutic but is evaluated in healthy subjects to determine the potential PK changes, safety, and tolerability when ASP6282 is administered alone and in the presence of itraconazole.

Targets

CYP3A4 (Cytochrome P450 3A4)CYP51A1 (Sterol 14α-demethylase)

Beyond the preview

Go deeper on ASP6282 + itraconazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ASP6282 + itraconazole.

Explore the full profile